cbd for pets research

AFP via Getty Images

The Making Of New York’s $150 Million ‘Cannabis Campus’

“Within three days I noticed that his back leg stopped shaking.” Cital reports, recalling how his elderly dog was more able to walk up the stairs and play. Cital says he has seen many dogs in his practice see similar improvement with CBD. “You just see the life brought back into them. and [you] get a few more quality years out of them comfortably.”

Blackstone To Sell The Cosmopolitan Of Las Vegas For $5.65 Billion

“I have never seen an added benefit to liposomal encapsulation with these molecules” he explains “I think in theory makes a lot of sense, but we haven’t seen the data to support that at this point.”

Cbd for pets research

EVERGREEN, COLO. — The animal health division of Canopy Growth Corporation, a company that researches and develops cannabis- and hemp-based consumer products, has completed two cannabidiol (CBD) companion animal studies that have been published in peer-reviewed veterinary industry journals.

Canopy animal health also had a study published in the February 2020 issue of Frontiers in Veterinary Science that shared a preliminary investigation of the safety of escalating CBD doses in healthy dogs.

The randomized, blinded, placebo-controlled trial saw 20 healthy adult cats randomly placed into five treatment groups, each group was then given up to 11 escalating doses of the trial formulations orally with at least three days between consecutive doses and found that both CBD and THC were generally well-tolerated by healthy cats, with only mild adverse reactions reported. The full study and its findings were published in the March 2021 issue of American Association of Feline Practitioners’ Journal of Feline Medicine and Surgery.

Cbd for pets research

FS, female spayed; MC, male castrated; Mix, mixed breed; SID, once daily; BID, twice daily.

Cmax, maximum concentration; Tmax, time of maximum concentration; T1/2 el, half-life of elimination; AUC 0-t, area under the curve (time 0–24 h); MRT, median residence time.

Serum pharmacokinetic of single oral dosing (2 mg and 8 mg/kg) of CBD oil in dogs.

Dogs included in the clinical trial

There was no significant difference in subjective veterinary lameness score and weight-bearing capacity throughout the study. Kinetic data was obtained from these dogs (data not shown), however 11 of the 16 dogs had significant bilateral disease (stifle, coxofemoral, or elbow) making evaluation of peak vertical force or symmetry tenuous at best. Unilateral disease in any of the aforementioned joints would be ideal to study the kinetic effects of this or similar extracts for pain relief leading to better objective outcomes. The population we used in our investigation was representative of dogs presenting in a clinical setting for management of OA and represents the typical OA patient.

During the trial, dogs were only allowed to receive NSAIDs, fish oil, and/or glucosamine/chondroitin sulfate without any change in these medications for 4 weeks prior to or during the 10-week study period as standard of care for the disease process. Other analgesic medications used, such as gabapentin and tramadol, were discontinued at least 2 weeks prior to enrolment. Dogs were excluded if they had evidence of renal, uncontrolled endocrine, neurologic, or neoplastic disease, or were undergoing physical therapy. Every dog was fed its regular diet with no change allowed during the trial.

Pharmacokinetics

Pharmacokinetics demonstrated that CBD half-life of elimination median was 4.2 h (3.8–6.8 h) for the 2 mg/kg dose, and 4.2 h (3.8–4.8 h) for the 8 mg/kg dose (Table ​ (Table1). 1 ). Median maximal concentration of CBD oil was 102.3 ng/mL (60.7–132.0 ng/mL; 180 nM) and 590.8 ng/mL (389.5–904.5 ng/mL; 1.2 uM) and was reached after 1.5 and 2 h, respectively, for 2 and 8 mg/kg doses. No obvious psychoactive properties were observed on evaluation at any time point during the 2 and 8 mg/kg doses over 24 h. These results led to dosing during the clinical trial at 2 mg/kg body weight every 12 h, due the cost prohibitive nature of 8 mg/kg dosing for most larger patients, the impractical nature of more frequent dosing, the volume of oil necessary and anecdotal reports surrounding 0.5-2 mg/kg dosing recommended by other vendors.

From the UHPLC-QQQ-MS data, peak areas were extracted for CBD detected in biological samples and normalized to the peak area of the internal standard CBD-d3, in each sample using Skyline (22) as well as an in-house R Script (www.r-project.org). CBD concentrations were calculated to nanograms per mL of serum as determined by the line of regression of the standard curve (r 2 = 0.9994, 0–1,000 ng/mL). For this assay, the limits of detection (LOD) and limits of quantification (LOQ) represent the lower limits of detection and quantification for each compound in the matrix of this study (23, 24). Pharmacokinetic variables were estimated by means of non-compartmental analysis, utilizing a pharmacokinetic software package (PK Solution, version 2.0, Montrose, CO, USA).